The similar differences observed for CSF DDC, FCER2, CRH, and MMP3 also in the PD data sets call for additional studies that evaluate the performance of these markers in other α-synucleinopathies (e.g., multiple system atrophy), other dementia types with motor dysfunctions (e.g., progressive supranuclear palsy, corticobasal degeneration) or other conditions with dopamine deficiency (e.g., psychiatry disorders). The gene discussed is CRH; the disease is progressive supranuclear palsy.